PA-023 ALTITUDE - ALTernating Induction Therapies to achieve Undetectable Disease Endpoints: Ph 1/2 Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-Risk Newly Diagnosed Multiple Myeloma
Year: 2026
Type: conference-abstract
Authors: Neha Korde, Carlyn Tan, Maximilian Merz, Sridevi Rajeeve, Malin Hultcrantz, Sham Mailankody, Kylee Maclachlan, Ross Firestone, Urvi A. Shah, Hamza Hashmi, Alexander Lesokhin, Hani Hassoun, Francesco Maura, Gunjan Shah, Eric Jurgens, Michael Scordo, Heather Landau, Julia Caple, Jayme O'Connor, Meredith Hyland, David Nemirovsky, Andriy Derkach, Sergio Giralt, Saad Z. Usmani
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7213914491